AXIM Biotechnologies, Inc. (OTC:AXIM) announced today the engagement of 624 Advisors, owned and managed by Dr. Alan J. Touch, as Chief Medical & Regulatory Affairs Advisor. Dr. Touch, a global regulatory specialist with over 30 years of experience, brings deep knowledge of the company's core technology, having co-invented the first ocular diagnostic technologies acquired by AXIM.
The engagement comes at a critical time for AXIM as it prepares for key regulatory and commercial milestones. Dr. Touch's expertise spans FDA regulation, ISO quality systems, clinical development, and manufacturing readiness, which will support the company's upcoming FDA 510(k) submissions and international regulatory expansion. His background includes leadership roles at Bausch & Lomb and Syneos Health, as well as founding 624 Advisors, a product development and regulatory consultancy.
“This strategic engagement is an important addition to the R&D and regulatory team at AXIM,” said Catalina Valencia, President and CEO. “Dr. Touch uniquely combines inventor-level knowledge of our technology with significant senior level experience in FDA regulation, ISO quality systems, clinical development, and manufacturing readiness. His involvement strengthens our regulatory strategy, quality foundation, and clinical execution, while positioning AXIM for efficient global expansion and long-term operational scale.”
Dr. Touch's role is designed to reduce reliance on external consultants and accelerate readiness for commercialization. His contributions will focus on advancing the TearScan® platform, a point-of-care diagnostic system that quantifies tear biomarkers for ocular and systemic health conditions. The TearScan platform enables clinicians to measure biomarkers with laboratory-grade accuracy in office settings, enhancing diagnostic confidence and treatment outcomes.
“I am pleased to work with AXIM at this important stage and to continue advancing technology I originally helped develop,” said Dr. Touch. “AXIM is building a strong foundation for market-sensitive and aware regulatory excellence and clinical credibility for its products. I look forward to supporting an excellent and cohesive scientific, marketing and operational team as they advance key submissions, strengthen quality systems, and prepare for long-term manufacturing and commercial success.”
Dr. Touch's background uniquely aligns with AXIM's current efforts and upcoming goals. He possesses inventor-level understanding of lactoferrin and immunoassay diagnostics, deep experience across FDA, EU MDR/IVDR, and global regulatory frameworks, and proven leadership in regulatory affairs, quality systems, clinical development, and manufacturing scale-up. The company expects this engagement to provide enhanced technical continuity, regulatory depth, and strategic execution capability.
AXIM Biotechnologies develops and commercializes rapid, point-of-care diagnostic tests focused on ocular and systemic health. For more information, visit www.aximbiotech.com.
